Robert Connelly, Elicio Therapeutics CEO
November 4, 2022 05:20 AM EDT
Financing
Startups
Coronavirus

Scoop: Call­ing off an IPO, a can­cer and Covid-19 vac­cine mak­er rais­es a Se­ries C

Kyle LaHucik

Senior Reporter

An on­col­o­gy and Covid-19 biotech led by a for­mer Flag­ship Pi­o­neer­ing ven­ture part­ner is close to wrap­ping up its Se­ries C af­ter a bear mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times